Litcius/Paper detail

Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC

Misako Nagasaka, Sai‐Hong Ignatius Ou

2021Journal of Thoracic Oncology33 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOncologyInternal medicineFirst lineLine (geometry)MathematicsGeometryLung Cancer Treatments and MutationsLung Cancer Research StudiesLymphoma Diagnosis and Treatment
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC | Litcius